{"id":67,"date":"2023-11-27T13:44:37","date_gmt":"2023-11-27T11:44:37","guid":{"rendered":"https:\/\/users.utu.fi\/jmmpal\/?p=67"},"modified":"2025-01-09T13:54:47","modified_gmt":"2025-01-09T11:54:47","slug":"kaljumyyrikon-has2-siirtogeenina-onkolyyttisessa-hsv-vektorissa","status":"publish","type":"post","link":"https:\/\/users.utu.fi\/jmmpal\/2023\/11\/27\/kaljumyyrikon-has2-siirtogeenina-onkolyyttisessa-hsv-vektorissa\/","title":{"rendered":"Kaljumyyrik\u00f6n HAS2 siirtogeenin\u00e4 onkolyyttisessa HSV-vektorissa"},"content":{"rendered":"

Tiede etenee hitaasti, mutta etenee kuitenkin. Noin 10 vuotta sitten<\/a> Naturessa julkaistiin havainto, ett\u00e4 kaljumyyrik\u00f6n pitk\u00e4n i\u00e4n ja sy\u00f6p\u00e4resistenssin taustalla vaikuttaa paksu solunulkoinen aine, jota tuottaa uniikilla tavalla mutatoitunut HAS2<\/em>-geeni. T\u00e4t\u00e4 tietoa hy\u00f6dynt\u00e4en kehitimme potentiaalisen sy\u00f6p\u00e4l\u00e4\u00e4kkeen, joka perustuu el\u00e4v\u00e4\u00e4n heikennettyyn herpesvirukseen, joka kantaa ja ilment\u00e4\u00e4 kaljumyyrik\u00f6n HAS2<\/em>-geeni\u00e4, ja testasimme sen tehoa aivosy\u00f6p\u00e4soluja (gradus IV astrosytooma) vastaan. Alustavat tulokset ovat aina alustavia, mutta sen verran lupaavia, ett\u00e4 tutkimustamme koskeva raportti julkaistiin Microorganisms-lehdess\u00e4. Tulevat vuosikymmenet n\u00e4ytt\u00e4v\u00e4t, tuleeko t\u00e4st\u00e4 toimiva hoitokeino sy\u00f6p\u00e4\u00e4 (tai vanhenemista) vastaan, mutta ainakin omasta mielest\u00e4ni el\u00e4mme kiinnostavia aikoja jo nyt.<\/p>\n

Herpes simplex virus (HSV) has proven successful in treating human cancer. Since the approval of talimogene laherparepvec (T-VEC) in 2015, HSV has been thoroughly researched to discover novel mechanisms to combat cancer and treat other diseases. Another HSV-based drug, beremagene geperpavec (B-VEC), received approval in 2023 to treat the rare genetic disease dystrophic epidermolysis bullosa, and was also the first clinically approved HSV vector carrying an extracellular matrix (ECM)-modifying transgene. The ECM is a network of macromolecules surrounding cells, which provides support and regulates cell growth and differentiation, the disruption of which is common in cancer. The naked mole rat (NMR) has a thick ECM and a unique mutation in the hyaluronan synthase 2 (HAS2) gene, which has been linked to the high cancer resistance of the species. To study the effect of this mutation in human cancer, we have developed an attenuated, replication-competent HSV vector expressing the NMR-HAS2 gene. The viral replication, transgene expression and cytotoxic effect of the novel vector was studied in glioma cells. Our results show that an attenuated, replication-competent HSV vector expressing a foreign ECM-modifying transgene, namely HAS2, provides an effective tool to study and combat cancer in humans.<\/p><\/blockquote>\n

Julkaisu ei ole maksumuurin takana, joten kuka tahansa tieteest\u00e4 kiinnostunut voi k\u00e4yd\u00e4 tutustumassa.<\/p>\n

L\u00e4hteet<\/h4>\n
    \n
  1. Palom\u00e4ki, J., Kalke, K., Orpana, J., Lund, L., Frejborg, F., Paavilainen, H., J\u00e4rvel\u00e4inen, H., & Hukkanen, V. (2023). Attenuated Replication-Competent Herpes Simplex Virus Expressing an ECM-Modifying Transgene Hyaluronan Synthase 2 of Naked Mole Rat in Oncolytic Gene Therapy. Microorganisms, 11(11), 2657. [doi<\/a>]<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Tiede etenee hitaasti, mutta etenee kuitenkin. Noin 10 vuotta sitten Naturessa julkaistiin havainto, ett\u00e4 kaljumyyrik\u00f6n pitk\u00e4n i\u00e4n ja sy\u00f6p\u00e4resistenssin taustalla vaikuttaa paksu solunulkoinen aine, jota tuottaa uniikilla tavalla mutatoitunut HAS2-geeni. T\u00e4t\u00e4 tietoa hy\u00f6dynt\u00e4en kehitimme potentiaalisen sy\u00f6p\u00e4l\u00e4\u00e4kkeen, joka perustuu el\u00e4v\u00e4\u00e4n heikennettyyn herpesvirukseen, joka kantaa ja ilment\u00e4\u00e4 kaljumyyrik\u00f6n HAS2-geeni\u00e4, ja testasimme sen tehoa aivosy\u00f6p\u00e4soluja (gradus IV astrosytooma) …read more<\/a><\/p>\n","protected":false},"author":6791,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wds_primary_category":0,"footnotes":""},"categories":[22],"tags":[32,31],"class_list":["post-67","post","type-post","status-publish","format-standard","hentry","category-virologia","tag-ecm","tag-geeniterapia"],"_links":{"self":[{"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/posts\/67","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/users\/6791"}],"replies":[{"embeddable":true,"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/comments?post=67"}],"version-history":[{"count":2,"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/posts\/67\/revisions"}],"predecessor-version":[{"id":72,"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/posts\/67\/revisions\/72"}],"wp:attachment":[{"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/media?parent=67"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/categories?post=67"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/users.utu.fi\/jmmpal\/wp-json\/wp\/v2\/tags?post=67"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}